NASDAQ:MEDS TRxADE HEALTH (MEDS) Stock Forecast, Price & News $6.62 -0.17 (-2.50%) (As of 09/27/2023 ET) Add Compare Share Share Today's Range$6.61▼$6.9450-Day Range$6.60▼$11.9452-Week Range$3.76▼$19.70Volume16,049 shsAverage Volume318,897 shsMarket Capitalization$4.50 millionP/E RatioN/ADividend YieldN/APrice Target$26.25 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media TRxADE HEALTH MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside296.5% Upside$26.25 Price TargetShort InterestHealthy1.56% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.89Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.11 out of 5 stars 3.5 Analyst's Opinion Consensus RatingTRxADE HEALTH has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $26.25, TRxADE HEALTH has a forecasted upside of 296.5% from its current price of $6.62.Amount of Analyst CoverageTRxADE HEALTH has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.56% of the float of TRxADE HEALTH has been sold short.Short Interest Ratio / Days to CoverTRxADE HEALTH has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in TRxADE HEALTH has recently increased by 125.81%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldTRxADE HEALTH does not currently pay a dividend.Dividend GrowthTRxADE HEALTH does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MEDS. Previous Next 3.8 News and Social Media Coverage News SentimentTRxADE HEALTH has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.86 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for TRxADE HEALTH this week, compared to 1 article on an average week.Search InterestOnly 7 people have searched for MEDS on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows6 people have added TRxADE HEALTH to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, TRxADE HEALTH insiders have not sold or bought any company stock.Percentage Held by Insiders48.40% of the stock of TRxADE HEALTH is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 4.12% of the stock of TRxADE HEALTH is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of TRxADE HEALTH is -1.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of TRxADE HEALTH is -1.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTRxADE HEALTH has a P/B Ratio of 12.04. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About TRxADE HEALTH (NASDAQ:MEDS) StockTRxADE HEALTH, Inc. operates as a health services IT company in the United States. The company focuses on digitalizing the retail pharmacy experience by optimizing drug procurement, prescription journey, and patient engagement. It operates the TRxADE drug procurement marketplace, which offers price transparency, purchasing capabilities, and other value-added services; and offers patient centric telehealth services under the Bonum Health brand name. The company was formerly known as Trxade Group, Inc. and changed its name to TRxADE HEALTH, Inc. in June 2021. TRxADE HEALTH, Inc. is based in Lutz, Florida.Read More MEDS Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MEDS Stock News HeadlinesSeptember 19, 2023 | americanbankingnews.comTRxADE HEALTH (NASDAQ:MEDS) Stock Price Down 7.2%September 7, 2023 | finance.yahoo.comSuperlatus Announces Planned Expansion into Pet Food MarketSeptember 27, 2023 | Behind the Markets (Ad)3 Words and a 3,000% ReturnIn October 2013, a scientist wrote 3 words on a piece of paper. They were simple words. A fiveyear-old could say them. But these three words could deliver you a 3,000% return in 2023 >>>September 7, 2023 | finance.yahoo.comTRxADE Health (NASDAQ:MEDS), Newly Merged With Superlatus, Is Gearing Up To Make Big Splashes In the $151 Billion Snacks Industry with its Acquisition of The Urgent Company Inc.September 6, 2023 | finance.yahoo.comTRxADE Health (NASDAQ:MEDS), Newly Merged With Superlatus, To Acquire The Urgent Company to Expand its Reach In The Sustainable Foods MarketSeptember 1, 2023 | benzinga.comWhat's Going On With TRxADE Health (MEDS) Stock?August 24, 2023 | benzinga.comTRxADE Health (NASDAQ: MEDS), Newly Merged With Superlatus, To Acquire The Urgent Company To Expand its Reach In The Sustainable Foods MarketAugust 24, 2023 | finance.yahoo.comSuperlatus Innovates $151 Billion US Snacking Market with Pulse-Based Protein Twists Under the Brave Robot BrandSeptember 27, 2023 | Stansberry Research (Ad)U.S. "Shadow Banks" About to Blow up again?Analyst who called Lehman crash says our biggest calamities (1907, 1929, 2007, etc) all start in the same spot--and it’s about to happen again. More here.August 22, 2023 | seekingalpha.comTrxade HEALTH to acquire The Urgent Company and portfolio of consumer brands from Perfect DayAugust 22, 2023 | benzinga.comTrxade Health (MEDS) Stock Is Moving Higher: What's Going On?August 22, 2023 | finance.yahoo.comSuperlatus, Newly Merged with TRxADE HEALTH, Agrees to Acquire The Urgent Company, Inc. and its portfolio of Consumer Brands from Perfect Day, Inc.August 14, 2023 | finance.yahoo.comTRxADE HEALTH, Inc. Announces Extension of Form 10-Q FilingAugust 11, 2023 | benzinga.comEarnings Preview: Trxade HealthAugust 3, 2023 | finance.yahoo.comNewly merged Entity Superlatus, Inc with Trxade Health, Inc. Appoints Leading CPG Management TeamJuly 31, 2023 | finance.yahoo.comTRxADE HEALTH, INC. to Report Q2 2023 Financial Results on Monday, August 14th at 6:00 p.m. Eastern TimeJuly 31, 2023 | finance.yahoo.comTRxADE HEALTH, Inc. Announces Closing of Acquisition of Superlatus, Inc.July 29, 2023 | finance.yahoo.comMEDS - TRxADE HEALTH, Inc.July 14, 2023 | seekingalpha.comTRxADE HEALTH amends merger agreement with SuperlatusJuly 14, 2023 | finance.yahoo.comTRxADE HEALTH, Inc. Amends Definitive Merger Agreement with Superlatus, Inc.June 30, 2023 | finance.yahoo.comSuperlatus, Inc. and TRxADE HEALTH, Inc. Sign Definitive Merger Agreement to Create a Global Strategic Platform for Food and Healthy Snack Marketplace and DistributionJune 27, 2023 | finance.yahoo.comSuperlatus, Inc. Announces New Appointments to the Management TeamJune 26, 2023 | msn.comWhat's Going On With TRxADE Health Stock?June 26, 2023 | benzinga.comShares of low-float TRxADE Health are trading higher on strong volume. The company announced on Friday that it will acquire Superlatus.June 23, 2023 | finance.yahoo.comTRxADE HEALTH, Inc. Issues Correction to Press Release Announcing its Anticipated Combination with Superlatus, Inc. (Correction Notice)June 23, 2023 | finanznachrichten.deTrxade Health, Inc.: Superlatus, Inc. to Combine with TRxADE HEALTH, Inc., to Create a Global Food Consolidation PlatformJune 23, 2023 | finance.yahoo.comSuperlatus, Inc. to Combine with TRxADE HEALTH, Inc., to Create a Global Food Consolidation PlatformSee More Headlines Receive MEDS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for TRxADE HEALTH and its competitors with MarketBeat's FREE daily newsletter. Email Address MEDS Company Calendar Last Earnings8/18/2023Today9/27/2023Next Earnings (Estimated)11/06/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Drugs, proprietaries, & sundries Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MEDS CUSIPN/A CIK1382574 Webwww.trxade.com Phone(800) 261-0281Fax800-265-6932Employees33Year FoundedN/APrice Target and Rating Average Stock Price Forecast$26.25 High Stock Price Forecast$26.25 Low Stock Price Forecast$26.25 Forecasted Upside/Downside+296.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($6.3484) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-3,470,000.00 Net Margins-43.29% Pretax Margin-43.84% Return on Equity-860.38% Return on Assets-56.36% Debt Debt-to-Equity RatioN/A Current Ratio0.49 Quick Ratio0.45 Sales & Book Value Annual Sales$11.45 million Price / Sales0.39 Cash FlowN/A Price / Cash FlowN/A Book Value$0.55 per share Price / Book12.04Miscellaneous Outstanding Shares680,000Free Float351,000Market Cap$4.50 million OptionableNot Optionable Beta1.90 The Best High-Yield Dividend Stocks for 2023Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMr. Surendra K. Ajjarapu (Age 52)Founder, Chairman, CEO & Sec. Comp: $354.23kMr. Prashant Patel (Age 49)Founder, Pres, COO, Interim Principal Financial & Accounting Officer and Director Comp: $147.04kDr. Ramesh KenchappaChief Scientific OfficerMr. David M. SaslowInhouse CounselMr. Jariel MoralesExec. VPKey CompetitorsBIMI International MedicalNASDAQ:BIMIWindtree TherapeuticsNASDAQ:WINTHeart Test LaboratoriesNASDAQ:HSCSHelius Medical TechnologiesNASDAQ:HSDTCNS PharmaceuticalsNASDAQ:CNSPView All CompetitorsInstitutional OwnershipBarclays PLCBought 4,801 shares on 9/21/2023Ownership: 0.706%Tower Research Capital LLC TRC Sold 15,616 shares on 8/14/2023Ownership: 0.314%Barclays PLCBought 4,801 shares on 8/3/2023Ownership: 0.706%View All Institutional Transactions MEDS Stock - Frequently Asked Questions Should I buy or sell TRxADE HEALTH stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for TRxADE HEALTH in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" MEDS shares. View MEDS analyst ratings or view top-rated stocks. What is TRxADE HEALTH's stock price forecast for 2023? 1 brokers have issued twelve-month price objectives for TRxADE HEALTH's stock. Their MEDS share price forecasts range from $26.25 to $26.25. On average, they expect the company's stock price to reach $26.25 in the next twelve months. This suggests a possible upside of 296.5% from the stock's current price. View analysts price targets for MEDS or view top-rated stocks among Wall Street analysts. How have MEDS shares performed in 2023? TRxADE HEALTH's stock was trading at $6.0390 at the beginning of 2023. Since then, MEDS stock has increased by 9.6% and is now trading at $6.62. View the best growth stocks for 2023 here. Are investors shorting TRxADE HEALTH? TRxADE HEALTH saw a increase in short interest during the month of September. As of September 15th, there was short interest totaling 14,000 shares, an increase of 125.8% from the August 31st total of 6,200 shares. Based on an average trading volume of 740,200 shares, the days-to-cover ratio is presently 0.0 days. Currently, 1.6% of the company's stock are sold short. View TRxADE HEALTH's Short Interest. When is TRxADE HEALTH's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023. View our MEDS earnings forecast. How were TRxADE HEALTH's earnings last quarter? TRxADE HEALTH, Inc. (NASDAQ:MEDS) announced its earnings results on Friday, August, 18th. The company reported ($0.77) EPS for the quarter, missing the consensus estimate of ($0.75) by $0.02. The business had revenue of $2.25 million for the quarter, compared to analyst estimates of $2.06 million. TRxADE HEALTH had a negative trailing twelve-month return on equity of 860.38% and a negative net margin of 43.29%. When did TRxADE HEALTH's stock split? Shares of TRxADE HEALTH reverse split on Thursday, June 22nd 2023. The 1-15 reverse split was announced on Thursday, June 22nd 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, June 22nd 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. What other stocks do shareholders of TRxADE HEALTH own? Based on aggregate information from My MarketBeat watchlists, some companies that other TRxADE HEALTH investors own include Advanced Micro Devices (AMD), Biocept (BIOC), iBio (IBIO), Ollie's Bargain Outlet (OLLI), OPKO Health (OPK), Alto Ingredients (PEIX), Tiziana Life Sciences (TLSA) and Trevena (TRVN). What is TRxADE HEALTH's stock symbol? TRxADE HEALTH trades on the NASDAQ under the ticker symbol "MEDS." Who are TRxADE HEALTH's major shareholders? TRxADE HEALTH's stock is owned by a number of institutional and retail investors. Top institutional investors include Barclays PLC (0.71%), Barclays PLC (0.71%) and Tower Research Capital LLC TRC (0.31%). Insiders that own company stock include Donald G Fell, Michael L Peterson, Prashant Patel and Surendra K Ajjarapu. View institutional ownership trends. How do I buy shares of TRxADE HEALTH? Shares of MEDS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is TRxADE HEALTH's stock price today? One share of MEDS stock can currently be purchased for approximately $6.62. How much money does TRxADE HEALTH make? TRxADE HEALTH (NASDAQ:MEDS) has a market capitalization of $4.50 million and generates $11.45 million in revenue each year. The company earns $-3,470,000.00 in net income (profit) each year or ($6.3484) on an earnings per share basis. How can I contact TRxADE HEALTH? TRxADE HEALTH's mailing address is 3840 Land O' Lakes Blvd., Land O' Lakes FL, 34639. The official website for the company is www.trxade.com. The company can be reached via phone at (800) 261-0281, via email at ir@trxade.com, or via fax at 800-265-6932. This page (NASDAQ:MEDS) was last updated on 9/27/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TRxADE HEALTH, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.